Perennial asthma
Conditions
Interventions
Open label phase: inhaled beclomethasone (250 mcg two times a day) and fenoterol (0,25 mg/3 Kg - for wheezing episodes), and a indivualized homeopathic medicine for each patient.
Once good asthma con
250 mcg - every other day (weeks 5-8)
discontinuation, if possible (weeks 9-12).
At the beginning of the step-down phase, patients will be randomly assigned to continue the individualized homeopathic medicine or to indistinguishable place
Drug
Sponsors
Universidade Federal de São Paulo
Ambulatório da Criança da Rede Pública de Saúde - Guarulhos/SP
Eligibility
Age
12 Years to 17 Years
Inclusion criteria
Inclusion criteria: Subjects with diagnosis of perennial asthma; using inhalatory beclometasone; presenting dyspnea; and or tightness in the chest; and or cough; and or effort dyspnea; and or other atopic diseases, such as rhinitis, conjunctivitis, dermatitis.
Exclusion criteria
Exclusion criteria: Severe perennial asthma presenting exacerbations requiring hospital admission or systemic medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome is the number of days of good clinical control during the reduction of inhaled corticotherapy. Expected outcome is a significantly greater mean in the group randomized to continue with Homeopathy group, as compared to placebo. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number (mean) of days of bronchodilator (B2-agonists) use; moderate exacerbations (defined as use of an emergency room not resulting in hospital admission); patients excluded due to asthma exacerbation indicating poor clinical control; adverse events. Expected outcome are significantly lower means in the group randomized to continue with Homeopathy group, as compared to placebo. | — |
Countries
Brazil
Contacts
Public ContactUbiratan Adler
Unidade de Saúde Escola da Universidade Federal de São Carlos
Outcome results
None listed